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ZNF143 transcription factor mediates cell survival
through upregulation of the GPX1 activity in the
mitochondrial respiratory dysfunction
W Lu*,1, Z Chen1,3, H Zhang1, Y Wang1, Y Luo2 and P Huang*,1
Mitochondrial respiratory dysfunction has intimate relationship with redox regulation. The key mechanism about how the
mitochondrial respiration-defective cells survive oxidative stress is still elusive. Here, we report that transcription factor zinc-
finger protein 143 (ZNF143) expression and glutathione peroxidase (GPX) activity are markedly increased in the mitochondrial
respiratory-defective cells induced by dominant-negative DNA polymerase c (POLGdn). In this work, investigation of the cellular
antioxidant glutathione (GSH) and enzyme GPX activity in the mitochondrial dysfunction revealed the presence of an increased
synthesis of GSH through the activation of GCLC (glutamate–cysteine ligase catalytic subunit) and GCLM (glutamate–cysteine
ligase regulatory subunit) gene expression, and also a positive upregulation of glutathione peroxidase 1 (GPX1) activity by the
transcription factor ZNF143. Significant increase in gene expression of SepSecS, the key enzyme responsible for selenocysteine
transfer RNA (tRNA) synthesis, further confirmed the activation of the selenocysteine synthesis pathway. By using both GPX1
and ZNF143 knockdown, we provided insight into the involvement of ZNF143 in promoting GPX1 activity and protecting cells
from oxidative damage and cisplatin treatment in the mitochondrial dysfunction. Furthermore, we reported the possible
regulation of mitochondrial transcription factor A (TFAM) in the mitochondrial dysfunction. Our findings delineate an important
antioxidant survival pathway that allows the mitochondrial-defective cells to survive oxidative stress and cisplatin treatment.
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The homeostasis of intracellular redox status is highly
regulated by the mitochondria and is likely to be important for
the pathogenesis of various human diseases. The mitochon-
drial dysfunction observed by mtDNA mutation in cancer has
increased reactive oxygen species (ROS) stress.1 To survive
the oxidative stress condition, cancer cells need to adjust their
antioxidant system to cope with the toxic effects of the free
radicals and initiate adaptation process, but the underline need
for regulatory mechanism of the survival pathway to deal with
ROS stress in the mitochondrial respiratory dysfunction is
elusive. Antioxidant systems are reported to be involved in
cancer cell survival and drug resistance.2 Thus, insights into
understanding the antioxidant regulatory mechanism in the
mitochondrial respiratory dysfunction may be important for the
design of novel therapeutic agents.
Free radicals can be eliminated by reducing equivalent
glutathione (GSH), an abundant cellular thiol and the major
determinant of cellular redox equilibrium, and GSH-coupled
antioxidant enzymes such as GSH peroxidases (GPXs) and
glutathione reductase to maintain redox homeostasis.3 GSH
peroxidase 1 (GPX1) is an abundant and ubiquitously
expressed selenoprotein and functions as a major intracellular
peroxide-scavenging enzyme.4,5 It utilizes GSH as a sub-
strate to catalyze the reduction of H2O2 and lipid peroxides.
6,7
The status of GSH and GPX and their regulatory mechanisms
in combat with ROS in the mitochondrial respiratory dysfunc-
tion is elusive. Glutamate–cysteine ligase, composed of
catalytic subunit (called GCLC) and regulatory subunit (called
GCLM), is important for GSH biosynthesis in combating a
variety of oxidative stress-related complications, thereby
activating the body’s own protective response.
Zinc-finger protein 143 (ZNF143) is the human homolog of
selenocysteine transfer RNA (tRNASec) gene-transcription-
activating factor. ZNF143 is required for the transcription
activation of tRNASec, which mediates the incorporation of
Sec into selenoproteins, such as GPX1.8 Sec (U) insertion
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into proteins is directed by translational recoding of specific
UGA codons located upstream of a stem-loop structure
known as Sec insertion sequence element. Selenoproteins
with known functions are oxidoreductases containing a single
redox-active Sec in their active sites. As a transcription factor,
ZNF143 is also involved in RNA-polymerase-II-dependent
gene expression. The expression of ZNF143 was reported to
be induced by DNA-damaging agents and is enhanced in
cisplatin-resistant cell lines.9 Recently, ZNF143 was found to
be highly expressed in multiple solid tumors and related to the
transcriptional regulation of DNA replication and cell-cycle-
associated genes.10
In this study, we adapted the molecular strategy by
induction of mitochondrial respiratory dysfunction through
tetracycline-controlled expression of dominant-negative DNA
polymerase g (POLGdn),11 and used this experimental model
system to investigate the adaptive changes associated with
ROS stress, and to identify major redox regulators in the
mitochondrial respiratory dysfunction, which reflect the meta-
bolic shift from oxidative phosphorylation to aerobic glyco-
lysis. We discovered that transcription factor ZNF143 protein
level is significantly increased in the metabolic change.
Through activating tRNASec gene transcription, ZNF143
increases GPX1 protein level and overall GPX activity to
combat ROS stress in the mitochondrial respiration dysfunc-
tion. Increased gene expression of SepSecS, the key enzyme
responsible for tRNASec synthesis, further confirms the
activation of the Sec synthesis pathway. Knockdown of
ZNF143 leads to decreased GPX activity, increased ROS
stress, increased sensitivity to cisplatin and causes massive
cell death in the mitochondrial respiratory-defective cells. This
observation is further confirmed by GPX1 gene knockdown.
Upregulation of GSH content through increased GSH synth-
esis by GCLC and GCLM gene expression is also observed.
Taken together, upregulation of cellular GSH antioxidant
system through increasing GPX activation pathway by
ZNF143 together with GSH synthesis could provide survival
advantages to combat oxidative stress and cisplatin treatment
in the mitochondrial respiration dysfunction.
Results
POLGdn expression led to defective oxygen respiration
and ROS generation. To investigate the survival mechan-
ism in terms of oxidative stress under mitochondrial
respiratory dysfunction, we first adapted an experimental
cell model where the mitochondrial respiratory status can be
regulated via a tetracycline-controlled dominant-negative
form of DNA polymerase g expression system.11 POLGdn
can effectively abolish mtDNA replication leading to respira-
tion defect.11–13 Induced expression of POLGdn by adding
doxycycline (Tet/on) to the culture medium led to a dramatic
decrease of mtDNA-encoded ATPase 6 gene expression
when compared with cells without doxycycline-induced
POLGdn expression (Tet/on day 0, or Tet/off) (Figure 1a).
As complex I deficiency could result in greater production of
ROS, we analyzed mtDNA-encoded complex I subunit ND1
gene expression. ND1 gene expression was sharply
decreased with POLGdn expression (Figure 1b). To confirm
that POLGdn expression in Tet/on situation could affect
mitochondrial respiration, cellular oxygen consumption capa-
city was measured. We found that oxygen consumption
ability was decreased in a time-dependent manner upon
POLGdn expression (Figure 1c). Concurrently, western blot
analysis detected that mtDNA-encoded cytochrome c oxi-
dase subunit II (COII) protein level was significantly
decreased and depleted around day 10 of POLGdn expres-
sion (Figure 1c, inset). As mitochondrion is regarded as one
of the major sites of ROS generation, the mitochondrial
dysfunction induced by POLGdn expression would be
predicted to cause profound increase in free radical stress
in POLGdn-induced mitochondrial respiratory dysfunction
cells. To explore this possibility, we measured intracellular
ROS levels by using the hydrogen peroxide-sensitive dye
dichlorofluorescein diacetate (DCF-DA). To our surprise, we
did not find significant increase on ROS level during the first 6
days of POLGdn induction, even when the mitochondrial
respiratory components were largely decreased (Figures 1d
and c). In comparison to their Tet/off counterparts, the
increase of cellular ROS levels was observed at day 9 and
markedly elevated at day 12 of POLGdn expression
(Figure 1d).
GSH redox status was altered at an early stage of the
mitochondrial dysfunction. To understand if the unaltered
ROS level in early stage of the mitochondrial dysfunction is
due to the increased antioxidant activity, we investigated
GSH antioxidant system, a major cellular antioxidant system
in combating ROS stress. Mitochondrial-defective Tet/on
cells showed significant increase in cellular total GSH when
compared with Tet/off cells (Figure 2a). Tet/on day 6 cells
displayed significant higher level of GSH along with Tet/on
day 9 and day 12 cells (Figure 2a). To understand the
mechanism of GSH level increase in mitochondrial-defective
cells, we first analyzed the genes involved in GSH synthesis.
Correlate to GSH level increase at day 6 of POLGdn
expression, gene expression of GCLC and GCLM, were
significantly increased (Figures 2b and c). Although GCLC
gene expression continuously increased with POLGdn
induction, GCLM gene expression was decreased at day
12 when compared with day 6, which corresponded to the
GSH level change. GSH synthetase (GSS) gene expression
did not have significant alteration during POLGdn induction
process (Figure 2d). Protein levels of the GCLC and GCLM
were also increased (Figure 2e). Taken together, these data
suggest that GSH synthesis pathway was activated and GSH
content was increased in the mitochondrial respiratory-
defective cells.
GPXs are the major antioxidant enzymes by using GSH as
substrate for the elimination of ROS. We investigated the
cellular GPX activity in Tet/on cells as a functional evaluation
in comparison to their Tet/off cell counterparts. Significant
GPX activity increase was observed even at an early stage of
the mitochondrial dysfunction (at day 3 of POLGdn induction),
when the increase of ROS level was not observed (Figure 3a).
As GPX1 serves as a key antioxidant enzyme, we first
analyzed GPX1 gene expression to further investigate GPX
activation mechanism. qRT-PCR data showed that GPX1
gene expression did not increase under the duration of
POLGdn induction (Figure 3b). These data suggest that GPX
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activity increase may due to post-transcriptional regulation of
GPX. Thus, GPX1 protein level was measured at indicated
days of POLGdn induction by western blot assay. The data
showed that GPX1 protein levels were increased constantly
after POLGdn expression (Figure 3c). Catalase, another
H2O2 detoxicification enzyme, was stable in the protein level
during POLGdn induction (Figure 3d), suggesting that GPX
activity increase is a major factor in detoxification of ROS in
the mitochondrial respiratory dysfunction.
ZNF143 has survival role through upregulation of the
GPX activity in the mitochondrial dysfunction. Tet/on
cells displayed higher GPX activity and increased GPX1
protein level, but with unaltered GPX1 gene expression,
which suggest that GPX1 activity is regulated at post-
transcription level. GPX1 is a selenoprotein and its activity
is dependent on the translational incorporation of the amino-
acid Sec to the activation site of the protein.14 Selenoprotein
synthesis is dependent on the presence of tRNASec, which
is regulated by transcription factor ZNF143.15 We speculated
that Tet/on cells may have higher ZNF143 level in
comparison to their Tet/off counterparts. ZNF143 mRNA
expression was evaluated by qRT-PCR and the data showed
that ZNF143 mRNA was significantly increased on day 3 of
POLGdn induction, the early stage of mitochondrial respira-
tory dysfunction, and its expression was further increased
after 9 days of POLGdn expression (Figure 4a). Concur-
rently, ZNF143 protein level was significant increased at day
4 of Tet/on cells and maintained at higher level afterwards
(Figure 4b). Sec is the only amino acid that does not have its
own tRNA snythetase. Its biosynthesis occurs on its cognate
tRNA. SepSecS is an enzyme that catalyzes the conversion
of O-phosphoseryl-tRNA(Sec) to selenocysteinyl-tRNA(Sec),
one of the major steps for Sec synthesis.16 To further
investigate whether Sec synthesis is activated, we tested
SepSecS gene expression using qRT-PCR and found that
the gene was significantly increased in a time-dependent
manner upon POLGdn induction (Figure 4c). To further
identify that Sec synthesis pathway was activated, tRNASec
level was evaluated by qRT-PCR. The data revealed that
tRNASec level was significantly upregulated after 3 days of
POLGdn expression (Figure 4d). To further prove that
ZNF143 is induced by the mitochondrial dysfunction, Tet/off
cells were treated with indicated mitochondrial respiratory
chain inhibitors. We observed that ZNF143 protein levels
were significantly increased with the treatments of these
inhibitors (Figure 4e). To ensure that mitochondrial dysfunc-
tion-induced ZNF143 activation is not limited to the POLGdn
Tet/on system, we measured GPX1 and ZNF143 protein
levels in mtDNA-depleted p1 cells (also called C6F) in the
comparison to control HL60 cells, another model of mito-
chondrial respiratory dysfunction, and observed increased
ZNF143 and GPX1 protein levels in p1 cells (Figure 4f).
These data strongly suggest that mitochondrial respiratory
dysfunction could induce transcription factor ZNF143 gene
expression and protein level increase, which further directs
increased tRNASec level, to activate Sec synthesis con-
tributing to selenoprotein GPX1 activity increase and protein
level increase.
To investigate the relationship between ZNF143 and GPX1
and the functional role of ZNF143 in mitochondrial respiratory
dysfunction, siRNA of ZNF143 was transfected 2 days after
Figure 1 POLGdn expression led to impaired mitochondrial respiration and ROS generation. (a) ATPase 6 mRNA level decreased in a time-dependent manner after
doxycycline-induced POLGdn gene expression. Real-time qRT-PCR was used to measure mRNA level of ATPase 6 and b-actin served as control (n¼ 3). Values are shown as
mean±S.D.; ***Po0.001. (b) ND1 mRNA level decreased in a time-dependent manner after doxycycline-induced POLGdn gene expression. Real-time qRT-PCR was used to
measure mRNA level of ND1 and b-actin served as control (n¼ 3). Values are shown as mean±S.D.; ***Po0.001. (c) Time-dependent reduction of oxygen consumption rate
following POLGdn expression. Tet/off cells were used as control (n¼ 3). Values are shown as mean±S.D.; ***Po0.001. (Inset) Time-dependent decrease of mtDNA-encoded
COII protein following POLGdn expression. COII protein level was assessed by western blot assay. b-Actin was probed as a loading control. (d) Cellular ROS levels were
significantly increased after profound mitochondrial respiration damage. Cellular H2O2 was measured by flow cytometry using 4mm DCF-DA as a fluorescent dye
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POLGdn induction. The knockdown efficiency was evaluated
after 4 days of siRNA transfection, considering that ZNF143
protein level is significantly increased at day 6 of POLGdn
induction (Figure 5a). ZNF143 knockdown led to the decrease
of GPX1 protein level when compared with scrambled siRNA
(scRNA) knockdown (Figure 5a). Concurrently, GPX activity
was significantly decreased in the ZNF143 knockdown cells
(Figure 5b). As GPX1 is an important ROS scavenger, we
speculate that ZNF143 knockdown would cause an increase
in ROS generation. We analyzed cellular H2O2 level on day 3
of Tet/on, which has either 1 day of ZNF143 siRNA or scRNA
transfection. We did not observe ROS alteration in the short
time of ZNF143 knockdown (Figure 5c, left). We then
analyzed cellular H2O2 level on day 5 of Tet/on cells, which
have 3 days of ZNF143 siRNA or scRNA transfection.
ZNF143 knockdown significantly increased cellular ROS
content (Figure 5c, right), which further proved the role of
ZNF143 in the maintenance of cellular redox balance through
the upregulation of antioxidant enzyme GPX function in the
mitochondrial respiratory dysfunction. Mitochondria have an
important role in the regulation of apoptosis, and mitochon-
drial respiratory-defective cells were reported to have less
sensitivity to chemotherapeutic agents commonly used in the
clinical treatment of cancer.17 We examined the effect of
mitochondrial defects on the cellular response to anticancer
agents, gemcitabine and taxol, through the comparison of the
drug sensitivity of Tet/off and respiration-defective Tet/on day
9 cells. We observed that the respiration-defective cells were
less sensitive than the Tet/off cells to both anticancer agents
(Figure 5d). The transcription factor ZNF143 was reported to
be overexpressed in cisplatin-resistant cells.9,22 We reasoned
that ZNF143 knockdown in respiration-defective cells might
increase the cellular sensitivity to cisplatin, an anticancer
agent commonly used in the clinic. Tet/on day 6 cells were
Figure 2 Changes in cellular GSH content and the expression of the genes responsible for GSH synthesis. (a) Comparison of cellular glutathione contents in Tet/off and
Tet/on cells at the indicated time points using a GSH assay kit from Cayman Chemical Co. (n¼ 3). Values are shown as mean±S.D.; ***Po0.001. (b) Real-time qRT-PCR
analysis of GCLC in Tet/off and Tet/on cells at the indicated time point. b-Actin was used as the sample control (n¼ 3). Values are shown as mean±S.D.; *Po0.05;
**Po0.01, ***Po0.001. (c) Real-time qRT-PCR analysis of GCLM in Tet/off and Tet/on cells at the indicated time points. b-Actin was used as the sample control (n¼ 3).
Values are shown as mean±S.D.; *Po0.05. (d) Real-time qRT-PCR analysis of GSS in Tet/off and Tet/on cells at the indicated time points. b-Actin was used as the sample
control (n¼ 3). Values are shown as mean±S.D. No significant difference of GSS was found between the control and the POLGdn-expressing samples. (e) GCLC and GCLM
protein level assessed by western blotting was increased after POLGdn expression. b-Actin was used as a loading control. Scanning and ImageJ software (a public domain
Java image processing program developed at the National Institutes of Health) was used for the quantification of western blot results. Results are expressed as integrated
optical density. Each sample was normalized to b-actin content
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transfected with either scRNA or ZNF143 siRNA for 24 h
followed by treatment with cisplatin for 48 h. As illustrated in
Figure 5e, cells with ZNF143 knockdown were more sensitive
to cisplatin treatment as shown by a substantial increase in the
percentage of cells with Annexin V/propidium iodide (PI)-
positive staining. There is a stable ZNF143 protein level
increase at day 6 of Tet/on (Figure 4b). We decided to
knockdown transiently the gene at day 6 of Tet/on by
transfecting ZNF143 siRNA at day 2 of Tet/on to investigate
the effect of ZNF143 knockdown. We observed that ZNF143
knockdown caused more than 25% cell death compared with
cells transfected with scRNA (Figure 5f). Altogether, our data
led to the conclusion that ZNF143 is an important survival
factor in the mitochondrial respiratory dysfunction through
increasing cellular GPX activity to allow mitochondrial-defective
cells to escape from higher oxidative stress. Targeted inhibition
of ZNF143 substantially increased cellular sensitivity to
cisplatin in respiration-defective Tet/on cells.
To further investigate a functional role of GPX1 activation in
mitochondrial dysfunctional cells, we transfected the plasmid
expressing nonspecific shRNA (NS-shRNA) and the plasmid
expressing GPX1 shRNA (GPX1-shRNA) in Tet/off cells.
GPX1 protein was effectively reduced by GPX1-shRNA as
determined by western blot analysis (Figure 6a). POLGdn
induction caused GPX1 protein level increase in NS-shRNA
plasmid-transfected control cells, whereas cells with GPX1
knockdown by GPX1-shRNA plasmid had no detectable
GPX1 expression even after POLGdn induction, further
confirming the GPX1 knockdown efficiency (Figure 6a). To
determine if GPX1 is the major antioxidant for the GPX
Figure 3 GPX activity and GPX1 protein level were constantly increased in the mitochondrial respiratory dysfunction induced by POLGdn expression. (a) Intracellular GPX
activity increased within the duration of POLGdn induction. Intracellular GPX activity was expressed as units/mg protein. Data correspond to means±S.D. from at least three
independent determinations of GPX. **Po0.01; ***Po0.001. (b) GPX1 mRNA level was unchanged within the indicated duration of POLGdn induction. Real-time qRT-PCR
analysis was used to assess GPX1 gene expression. b-Actin was used as the sample control (n¼ 3). Values are shown as mean±S.D. No significant change in gene
expression was observed. (c) Time-dependent increase in the protein level of GPX1 following POLGdn expression. Left panels show representative GPX1 protein level with
POLGdn induction assessed by western blotting. b-Actin was probed as a loading control. Right panels show quantification of western blot results using scanning and ImageJ
software. Results are expressed as integrated optical density. Each sample was normalized to b-actin content. Each bar represents the mean±S.E.M. of three independent
experiments. *Po0.05; **Po0.01; ***Po0.001. (d) Catalase protein level was unaltered within the indicated duration of POLGdn induction. Left panels show representative
catalase protein levels assessed by western blotting. b-Actin was probed as a loading control. Right panels show quantification of western blot results using scanning and
ImageJ software. Results are expressed as integrated optical density. Each sample was normalized to b-actin content. Each bar represents the mean±S.E.M. of three
independent experiments. No significant change was observed
ZNF143 mediates cell survival in mitochondrial dysfunction
W Lu et al
5
Cell Death and Disease
activation in the mitochondrial dysfunction, GPX activity was
measured. Cells with NS-shRNA plasmid showed increased
GPX activity after POLGdn induction, whereas cells with
GPX1 knockdown did not have any GPX activity increase after
POLGdn induction and even lower than the Tet/off control
cells (Figure 6b). These data further confirm that GPX activity
increase mainly comes from GPX1. To test the effect of GPX1
knockdown in response to cisplatin treatment in the respira-
tion-defective cells, we induced POLGdn expression for 7
days in either NS-shRNA or GPX1-shRNA stably transfected
POLGdn Tet/on models followed by treatment of cisplatin for
48 h. As illustrated in Figure 6c, Tet/on day 9 cells with GPX1
knockdown showed approximately 25% more cell death
compared with same stage of Tet/on cells with scramble
vector transfection under cisplatin treatment. To examine the
effect of GPX1 knockdown on cell death of long time Tet/on
cells, Annexin V/PI double staining assay was used. Figure 6d
indicates that Tet/on day 12 cells with GPX1 knockdown
resulted in approximately 20% more cell death than same
stage of Tet/on cells with scramble vector transfection.
There was a significant increase in cellular GSH and an
upregulation of GPX activity, which mainly came from GPX1
activation. These data together suggest that expression of
POLGdn induced mitochondrial dysfunction, which in turn led
to an increase in cellular GSH content and an increase in
ZNF143-mediated GPX antioxidant activity in protecting
mitochondrial respiratory-defective cells from oxidative
damage and cisplatin treatment.
Figure 4 ZNF143 gene expression and protein level were significantly increased in the cells with mitochondrial respiratory dysfunction. (a) ZNF143 mRNA level, as
determined by real-time qRT-PCR, was significantly increased after POLGdn induction by doxycycline. b-Actin was used as the sample control (n¼ 3). Values are shown as
mean±S.D.; **Po0.01; ***Po0.001. (b) ZNF143 protein level detected by western blot was increased upon POLGdn expression at indicated time points. b-Actin was
probed as a loading control. Upper panels show representative ZNF143 protein levels assessed by western blot. Lower panels show quantification of western blot results using
scanning and ImageJ software. Results are expressed as integrated optical density. Each sample was normalized to b-actin content. Each bar represents the mean±S.E.M.
of three independent experiments. *Po0.05; ***Po0.001. (c) SepSecS gene expression, as determined by qRT-PCR, was significantly increased after 3 days of POLGdn
induction by doxycycline. b-Actin was used as the sample control (n¼ 3). Values are shown as mean±S.D.; **Po0.01; ***Po0.001. (d) tRNASec expression, as
determined by qRT-PCR, was significantly increased after 3 days of POLGdn induction. b-Actin was used as the sample control (n¼ 3). Values are shown as mean±S.D.;
**Po0.01; ***Po0.001. (e) Western blot analysis of ZNF143 protein level in Tet/off cells were treated with mitochondrial respiratory chain inhibition agents, rotenone
(100 nM), antimycin (5mM) or sodium azide (500mM), for 24 h, respectively. b-Actin was probed as a loading control. ZNF143 fold change was quantified by scanning and
ImageJ software. Results are expressed as integrated optical density. Each sample was normalized to b-actin content. (f) ZNF143 and GPX1 protein levels were increased in
mitochondrial respiration-defective p1 cells. Left panels show representative ZNF143 and GPX1 protein levels in mitochondrial respiration-defective p1 (C6F) cells as
compared with their parental HL60 cells using western blot assay. b-Actin was probed as a loading control. Right panels show quantification of western blot results using
scanning and ImageJ software. Results are expressed as integrated optical density. Each sample was normalized to b-actin content. Each bar represents the mean±S.E.M.
of three independent experiments. *Po0.05; **Po0.01
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ZNF143 expression could not protect TFAM from
degradation in mitochondrial dysfunction. ZNF143 was
previously reported as one of the several transcription factors
responsible for maintaining the normal transcription levels of
the mammalian mitochondrial transcription factor A (TFAM),
a nuclear-encoded mitochondrial transcription factor that is
indispensible for the expression of key mitochondrial-
encoded genes and for the replication of mitochondrial
DNA.18 To investigate the effect of ZNF143 on TFAM
regulation in the mitochondrial respiratory dysfunction, TFAM
gene expression was evaluated with qRT-PCR and did not
have corresponding increase during POLGdn induction
(Figure 7a). The data showed that the expression of TFAM
transcription factor (nuclear respiratory factor-1 (NRF-1)) and
activators such as peroxisome proliferator-activated receptor
g co-activator 1a (PGC-1a) and PGC-1-related coactivator
Figure 5 ZNF143 protein level increase is important for the increase of GPX1 activity in the mitochondrial-defective cells to survive oxidative stress. (a) GPX1 protein level
was decreased after ZNF143 siRNA knockdown on day 6 of Tet/on cells. At 2 days after POLGdn expression, cells were transiently transfected with nonspecific scramble
siRNA (scRNA) or ZNF143 siRNA for 4 days in a doxycycline medium. Western blotting was conducted to confirm ZNF143 knockdown. b-Actin served as a loading control. (b)
GPX activity significantly decreased after ZNF143 gene knockdown. Tet/on day 6 cells or Tet/on day 6 cells with scRNA transcient transfection were used as control (n¼ 3).
Values are shown as mean±S.D.; ***Po0.001. (c) ZNF143 gene knockdown at day 3 of Tet/on cells (1 day after ZNF143 siRNA transfection) has same H2O2 level as its
counterpart with scRNA knockdown (left). ZNF143 gene knockdown at day 5 of Tet/on cells (3 days after ZNF143 siRNA transfection) has higher H2O2 level than its
counterpart with scRNA knockdown (right). DCF-DA was used as a probe and detected by flow cytometry. (d) Comparison of drug sensitivity in Tet/off and Tet/on day 9 cells.
Cells were incubated with the indicated concentrations of gemcitabine (dFdC) and taxol for 72 h, and cell death was analyzed by flow cytometry after double staining with
Annexin V and PI. (e) Tet/on cells with ZNF143 knockdown were sensitive to cisplatin treatment. Tet/on day 6 cells were transfected with ZNF143 siRNA or scramble siRNA
(scRNA) for 24 h followed by treatment with cisplatin at the indicated concentration for 48 h. Cell death was measured by flow cytometry after double staining with Annexin V
and PI. (f) ZNF143 gene knockdown caused massive cell death on day 6 of Tet/on cells (4 days after ZNF143 siRNA transfection) when compared with its counterpart with
scRNA knockdown. Cell death was detected by Annexin V/PI double stain and detected by flow cytometry
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(PRC) did not have significant alteration even after 6 days of
POLGdn induction (Figure 7a). TFAM protein was signifi-
cantly decreased on day 2 and became undetectable by day
4 after POLGdn induction (Figure 7b). To further confirm that
TFAM protein might be destabilized as a consequence of
reduced mtDNA content, we used 20,30-dideoxycytidine
(ddC), a nucleoside analog known to incorporate efficiently
into mtDNA and terminate its replication, as another method
to examine its effect on TFAM protein levels. Treatment of
Tet/off cells with ddC led to a time-dependent decrease of
TFAM protein (Figure 7c). These findings suggest that lower
mtDNA was associated with decreased TFAM protein level,
and are consistent with the report that p1 cells have
significant decrease of TFAM protein level.19 Interestingly,
the proteasome inhibitor MG132 partially prevented the
disappearance of TFAM protein in Tet/on cells, whereas
the caspase inhibitor Z-VAD did not suppress TFAM
degradation (Figure 7d), suggesting that TFAM was
degraded mainly by proteasome or proteasome-like structure
when mtDNA replication was inhibited by POLGdn induction.
These data suggest that TFAM is mainly regulated at post-
transcription level, but not transcriptional level in the
mitochondrial respiration dysfunction induced by POLGdn.
Discussion
We propose that oxygen consumption by respiration repre-
sents a fundamentally important function of mitochondria,
which is to keep the essential redox homeostasis. By using a
Tet/on-inducible system to regulate POLGdn expression, we
have created a pair of respiring and non-respiring human cell
lines to investigate possible mechanisms of antioxidant status
to the oxidative stress in the mitochondrial respiratory
dysfunction, which also reflect the metabolic switch from
mitochondrial oxidative phosphorylation to aerobic glycolysis.
POLGdn expression in Tet/on cells caused defective mito-
chondria with depletion of mtDNA-encoded gene expression
and protein expression responsible for functional mitochon-
drial respiratory chain, decreases of mitochondrial respiration.
Mitochondrial dysfunction induced by POLGdn has a pro-
found impact on the balance between the ROS and
antioxidant homeostasis. From the study, we have estab-
lished that ZNF143 is responsive to genetic or pharmacolo-
gical disruption of mitochondrial respiration and that ZNF143
can regulate GPX1 level and GPX activity, an event that
promotes the antioxidant defense of the compromised
respiration with oxidative stress. This study revealed that
increase of GPX1 protein level and GPX activity by ZNF143
may be an important adaptive mechanism for cell survival
and drug resistance in the mitochondrial respiratory dysfunc-
tion, as knockdown of these genes in the mitochondrial
dysfunction increased sensitivity to cisplatin treatment and
caused massive cell death. Upregulated GPX activity is
orchestrated via increased cellular GSH level in the mitochon-
drial-defective cells, which further emphasize the role of
antioxidants in the defense against the cellular oxidative
stress with mitochondrial dysfunction (Figure 8). Thus,
ZNF143 and GPX1 together with increased GSH synthesis
may have key roles in the control of metabolic network that
regulates cell survival and oxidative defense in the mitochon-
drial respiratory dysfunction. Cancer cells often display
different degrees of mitochondrial respiratory dysfunction
with resistance to the common chemotherapeutic drug
intervention; thus, the identification of pathways that promote
cell survival under the mitochondrial respiratory-defective
metabolic status may have therapeutic implications.
Mitochondrial dysfunction is an important abnormality in
cancer.20,21 Mitochondrial-defective p1 cells were reported to
be resistant to many anticancer agents.17 The drug sensitivity
Figure 6 GPX1 is the major factor contributing to GPX activity for the survival of
cells in mitochondrial respiratory dysfunction. (a) Cells with GPX1 stable knockdown
by shRNA plasmid (GPX1-shRNA) showed no detectable GPX1 protein even with
POLGdn induction, wheraas cells with scrambled plasmid knockdown (sc-shRNA)
showed increased GPX1 protein level upon POLGdn expression. COII protein level
was used as an indicator of effective POLGdn induction and b-actin was probed as
a loading control. (b) GPX1 knockdown (GPX1-shRNA) significantly decreased
cellular GPX activity in Tet/off cells and activity increase was not observed after
POLGdn induction, whereas scramble knockdown (NS-shRNA) cells showed
increased GPX activity in a time-dependent manner with POLGdn induction. Data
correspond to means±S.D. from at least three independent determinations of
GPX. ***Po0.001. (c) Tet/on cells with GPX1 knockdown were sensitive to cisplatin
treatment. After 7 days of Tet/on, cells with NS-shRNA or GPX1-shRNA were
treated with indicated concentration of cisplatin for 48 h. Cell death was measured
by flow cytometry after double staining with Annexin V and PI. (d) GPX1 knockdown
by its specific shRNA plasmid showed substantial increase in cell death by day 12 of
Tet/on as detected by Annexin V/PI double staining. Cells with scrambled plasmid
knockdown (sc-shRNA) served as control
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of cancer cells is governed by the complex pathways involved
in the pathogenesis of cancer, and understand the fact that the
survival pathway under the metabolic status may become a
primary theme of molecular therapies. The transcription factor
ZNF143 is stress induced and overexpressed in cisplatin-
resistant cells.9,22 The development of cisplatin resistance by
tumor cells is a major clinical limitation in cancer chemother-
apy. One of the several possible mechanisms of resistance is
the increased activity of intracelluar pathways of thiol
production, such as GSH, which can contribute to the
detoxification of cisplatin.23 GCLC, a key rate-limiting enzyme
involved in GSH biosynthesis, was also shown to be
associated with cisplatin resistance.24 ZNF143 knockdown
in prostate cancer caused increased sensitivity for cisplatin.9
Our data have revealed that in orchestra with the
increased activity of GCLC and GSH synthesis, ZNF143
upregulates cellular GPX activity to protect cells from
oxidative stress induced by mitochondrial dysfunction. Tar-
geted inhibition of ZNF143 substantially increased cellular
sensitivity to cisplatin in respiration-defective Tet/on cells. The
signal pathway could serve as a potential target for
therapeutic intervention as cisplatin-resistant cells also dis-
play mitochondrial defects.25
TFAM, one of the key factors for the mtDNA replication and
transcription, was reported as a downstream target of
ZNF143.18 POLGdn expression upon doxycycline induction
did not induce TFAM gene upregulation even though higher
ZNF143 protein level was observed. Instead, TFAM protein
was depleted through a pathway that may be similar to the
proteasome activation mechanism. To our surprise, other
TFAM transcription regulators such as PGC-1a, PRC and
NRF-1 did not respond to the early stage of mitochondrial
dysfunction, and their mRNA levels remained stable even
after 6 days of POLGdn induction. These data imply that
PGC-1a, a master regulator of mitochondrial function, is not the
early response gene in the mitochondrial respiratory dysfunc-
tion. This is in contrast to the prompt expression ofZNF143 and
GPX1 genes in the mitochondrial respiratory dysfunction.
Materials and Methods
Cell lines and reagents. Tet/off T-Rex 293 cells were cultured in the DMEM
culture medium supplemented with 10% tetracycline-free FBS in 5% CO2 at 37 1C
in the presence of 100mg/ml zeocin and 5mg/ml blasticidin as the selection agents.
Tet/on cells were maintained in DMEM supplemented with 10% FBS, 1 mmol/l sodium
pyruvate, 50 mmol/l uridine, 0.47% glucose and 100mg/ml zeocin, 5mg/ml blasticidin
and 1mg/ml doxycycline.11 HL60 and its derived C6F (p1) cells were maintained as
described.17 MG132, PI, rotenone, sodium azide and antimycin A were obtained from
Sigma (St Louis, MO, USA). 2,7-DCF-DA was obtained from Invitrogen (Carlsbad,
CA, USA). Z-VAD-FMK was purchased from Promega (Fitchburg, WI, USA) and
FITC Annexin V was from BD Biosciences (Franklin Lakes, NJ, USA).
RNA preparation and real-time qRT-PCR. Total RNA isolation and
cDNA synthesis were carried out as described previously.26 The mRNA
expression of ZNF143, GPX1, GCLC, GCLM, GSS, SepSecS, ATPase 6,
tRNASec, NRF-1, PGC-1a, PRC and TFAM were analyzed by qRT-PCR using
primers as described27 or otherwise as listed below: ZNF143 forward,
Figure 7 ZNF143 expression could not protect TFAM from degradation in
mitochondrial dysfunction. (a) Increased ZNF143 expression did not upregulate
mRNA expression of TFAM as measured by qRT-PCR. TFAM gene expression did
not change even after 6 days of POLGdn induction. TFAM transcriptional regulators,
such as NRF-1, PGC-1a and PRC gene expression, did not have significant
alteration after mitochondrial dysfunction. b-Actin was used as internal control. Data
are shown as mean±S.D. of triplicate samples from three independent
experiments. (b) Disappearance of TFAM protein following inhibition of mtDNA
synthesis by POLGdn expression as determined by western blot assay. b-Actin was
probed as a loading control. (c) Dramatic decrease of TFAM protein following
inhibition of mtDNA synthesis by 0.2mM ddC as determined by western blot assay.
b-Actin was probed as a loading control. (d) Suppression of TFAM protein
degradation by the proteasome inhibitor MG132, but not by pancaspase
inhibitor Z-VAD. After doxycycline-induced POLGdn expression for 24 h, cells were
treated with the indicated inhibitors for additional 24 h. Protein lysates were
subject to western blot analysis for TFAM protein and b-actin was probed as a
loading control
Figure 8 Schematic illustration of ZNF143 function in mitochondrial dysfunc-
tion. Disruption of mitochondrial respiration by either genetic or pharmacological
approaches led to the prompt increase in the function of transcription factor
ZNF143. By increasing the expression of tRNASec, elevated ZNF143 upregulates
GPX activity. Increased GPX activity is orchestrated via increased cellular
glutathione synthesis by transcriptional upregulation of glutathione synthesis
enzyme GCLC and GCLM, which together serve as antioxidants in the defense
against the cellular oxidative stress and resistant to cisplatin treatment in the
mitochondrial respiratory dysfunction
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50AGACTTGGCAGCATTCCATAC30 and reverse, 50CCATTGGATGTTGCTAC
TAAGGT30; GPX1 forward, 50CTCTTCGAGAAGTGCGAGGT30 and reverse,
50GATGTCAGGCTCGATGTCAA30; GCLC forward, 50GGCACAAGGACGTTC
TCAAGT30 and reverse, 50CAAAGGGTAGGATGGTTTGGG30; GCLM forward,
50TGTGTGATGCCACCAGATTTG30 and reverse, 50CGTGCGCTTGAATGTCAG
G30; GSS forward, 50CTCTACGGCTCACCCAATGC30 and reverse, 50TCGTC
GGATCACATGGATGTT30; SepSecS forward, 50ATTGGACGATCCGGTGATA
TTTC30 and reverse, 50AAAGCAGTTGGCTACTGTATGG30; PGC-1a forward,
50-ACTCAGCAGCAGTTGACCCT30 and reverse, 50GGACTAGGAGAAGCAGGG
CT30; ATPase 6 forward, 50CTGTTCGCTTCATTCATTGCC30 and reverse, 50GT
GGCGCTTCCAATTAGGTG30; tRNASec forward, 50CGGATGATCCTCAGTGG
TCT30 and reverse, 50CGGGCAACAAGCAAAATAAG30; ND1 forward, 50AACA
TACCCATGGCCAACCT30 and reverse, 50GGCAGGAGTAATCAGAGGTC30;
b-actin forward, 50GCATCGTCACCAACTGGGAC30 and reverse, 50ACCTGG
CCGTCAGGCAGCTC30 was used as internal control. For tRNA expression, the
reverse primer of tRNASec was annealed to RNA and reverse transcribed
(Fermentas, Burlington, ON, Canada). The forward primer of tRNASec was later
on added for the amplification of the cDNA.28 Real-time qRT-PCR was performed
and normalized by measuring average cycle threshold (Ct) ratios between
the gene of interest and b-actin gene using a ViiA 7 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA).
Western blot analysis. Proteins from whole cell lysates were separated
by SDS-PAGE and transferred onto nitrocellulose membranes. The membranes
were probed with the following primary antibodies: anti-GCLC (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA), anti-GCLM (Novus Biologicals, Littleton,
CO, USA), anti-TFAM (Aviva Systems Biology, San Diego, CA, USA), anti-COII
(Invitrogen), anticatalase (Calbiochem, Darmstadt, Germany), anti-b-actin (Sigma),
anti-GPX 1 (Lab Frontier, Seoul, Korea) and anti-ZNF143 (Novus). The bound
primary antibodies were then probed with their respective secondary antibodies
conjugated to horseradish peroxidase. Immunolabeled proteins were detected by
using a SuperSignal enhanced chemiluminescence kit (Pierce, Rockford, IL, USA)
and autoradiography. For sequential blotting, the membranes were stripped by
using stripping buffer (Pierce) and reprobed with other antibodies or b-actin-specific
antibody to provide a loading control.
Determination of cellular ROS and oxygen consumption. Mea-
surement of cellular ROS and oxygen consumption were performed as
described.11,17,29 Briefly, cellular ROS of Tet/off and Tet/on cells were measured
with 4 mM DCF-DA using a BD Biosciences FACSCalibur flow cytometer and
analyzed using the CellQuest software (Becton Dickinson, San Jose, CA, USA).
DCF-DA was detected as FL1 (525±20 nm). Oxygen consumption was measured
with a Clark-type oxygen electrode system (Oxytherm, Hansatech Instrument,
Cambridge, UK).11,17
Assays for cellular GSH and GPX enzyme activity. Cellular GSH
was measured using a GSH assay kit (Cayman Chemical Co., Ann Arbor, MI,
USA) according to the manufacturer’s recommendation. Briefly, cell extracts
were prepared by sonication and deproteination and cellular total GSH was
detected by measuring the product of glutathionylated DTNB by UV spectro-
photometer at 405 nm. The standard curve was also generated to calculate
cellular GSH contents.
GPX enzyme activity in the cell lysates was determined by coupled chemical
reactions using GSH reductase and the GPX assay kit (Cayman Chemical Co.). The
reaction mixture contained 50 mM sodium phosphate, 0.4 mM EDTA buffer (pH
7.0), 2 mM GSH, 0.2 mg/ml NADPH, 0.1 U of GSH reductase and a certain volume
of cell extract; 0.001% H2O2 was added to initiate the reaction. The kinetics of
NADPH oxidation was monitored for 5 min at 340 nm. Cellular GPX activity was
calculated based on equal concentrations of protein extracts determined by BCA
protein assay kit (Pierce) with BSA as a standard. Results were expressed as units/
mg protein.
Knockdown analysis using siRNA/shRNA methods. Double-
strained siRNA of ZNF143 was generated from Stealth Select RNAi (Invitrogen;
HSS111600) with 25 bp oligonucleotides: 50-AUAAGCUGUGGUACCAUCUUC
CAGC-30 and 50-GCUGGAAGAUGGUACCACAGCUUAU-30. Scramble control
siRNA was purchased along with siRNA of ZNF143. SureSilencing shRNA
plasmids for human GPX1 were purchased from SABiosciences (Frederick,
MD, USA) and transfected into Tet/on T-Rex 293 cell model bearing inducible
POLGdn gene expression.11 Transfection by using Lipofectamine 2000 and colony
selection by using puromycin were performed according to the manufacturer’s
instruction. Nonspecific shRNA plasmid sequencing is 50-TAGAGAAGTCCCGCCT
CATAA-30.
Determination of cell death. Apoptosis was determined by flow cytometry
using the Annexin V and PI double staining method. Briefly, after drug treatment,
cells were collected and washed twice with cold PBS and then stained with
Annexin V for 15 min at room temperature in dark followed by staining with PI. The
levels of apoptosis in Annexin V/PI assay were determined by measuring the
fluorescence of the cells using a FACSCalibur flow cytometer equipped with
CellQuest Pro software. A total of 10 000 cells were analyzed per sample.
Statistical analyses. The Kolmogorov–Smirnov test (CellQuest Pro soft-
ware; Becton Dickinson) was used to evaluate the significant difference between
control and test samples in flow cytometry analysis. For comparison of the
statistical differences of more than two groups, one-way ANOVA and Newman–
Keul’s multiple comparison test was used. All other statistical significant difference
analyses were evaluated using Student’s t-test (Prism GraphPad, San Diego, CA,
USA). A P-value o0.05 was considered statistically significant.
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